Watch for upcoming FDA interactions to define registrational pathways and for 1H 2027 data on additional follow-up and registrational dose selection (4B vs 6B cells/dose). The compressed dosing schedule and dose escalation are key catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $1.59entry
- T+1 · 7d ago −15.09%α −14.73% · $1.35
- T+5 · 18h ago −23.90%α −22.21% · $1.21
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nkarta reported initial Phase 1/2 clinical data for NKX019, an allogeneic CAR NK cell therapy, in myositis and systemic sclerosis at ACR Convergence 2026. At the 4 billion cells per dose level, 83% of myositis patients and 86% of systemic sclerosis patients achieved clinically meaningful responses, with a favorable safety profile (no CRS, ICANS, or GvHD in 40 patients). The company plans FDA interactions for registrational pathways and expects additional data in 1H 2027.
Key Facts
- In myositis, 5/6 (83%) patients at 4B cells/dose with >=3 months follow-up achieved moderate or major TIS responses.
- In systemic sclerosis, 6/7 (86%) patients at 4B cells/dose achieved rCRISS-25 or greater by Day 90; 5/7 (71%) achieved rCRISS-50 or greater.
- Median mRSS reduction of 15 points at Day 90 in SSc; 5/7 (71%) achieved >=50% reduction from baseline.
- No deaths, no treatment discontinuations due to AEs, no CRS, ICANS, IEC-HS, or GvHD among 40 patients across five indications.
- Company amended Ntrust protocols to compress dosing to Days 0, 2, 4 and plans to evaluate 6B cells/dose.
- Company anticipates FDA interactions to discuss registrational pathways in both myositis and systemic sclerosis.
- Cash, cash equivalents and investments of $216M as of Sep 30, 2026; expected cash runway into 2029.
Financial Impact
No revenue or earnings data; clinical-stage biotech with $216M cash runway into 2029. Positive efficacy and safety data could support regulatory path and valuation.
Risk Factors
- Preliminary data from small patient numbers with limited follow-up; results may change as more data become available.
- FDA may not agree with proposed registrational pathways or dose selection.
- Changes to dosing schedule or dose level may not achieve anticipated results or may raise safety concerns.
- No head-to-head studies vs other therapies; cross-trial comparisons are cautioned.
- Company has no approved products and a history of losses; dependent on NKX019 clinical success.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001787400-26-000027 |
| Document: nktx-ex99_1.htm | 0001787400-26-000027 |
| Document: nktx-ex99_2.htm | 0001787400-26-000027 |
| Document: 0001787400-26-000027-index-headers.html | 0001787400-26-000027 |
| Document: 0001787400-26-000027-index.html | 0001787400-26-000027 |
| Document: 0001787400-26-000027.txt | 0001787400-26-000027 |
Track record
13 reports on NKTX
5 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +31.21% at T+5 after the Nov 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 9, 20267d ago Press Release Bullish 7/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 6, 202610d ago 8-K Neutral 3/10 Entry $1.59 to $1.35 Now $1.21 −23.90% ▼ −15.09% −14.73% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Bearish 5/10 Entry $1.73 to $1.59 Now $1.21 +30.06% ▲ +8.09% +10.46% vs SPY
- Aug 10, 202614w ago 8-K Bearish 6/10 Entry $2.33 to $2.39 Now $1.21 +48.07% ▼ −2.58% −2.32% vs SPY
- May 12, 202626w ago Press Release Neutral 4/10 Entry $3.06 to $3.06 Now $1.21 −60.46% · 0.00% +0.00% vs SPY
- Apr 15, 202630w ago Press Release Bullish 7/10 Entry $2.80 to $3.47 Now $1.21 −56.79% ▲ +23.93% +22.71% vs SPY
- Apr 6, 202632w ago EFFECT Bearish 7/10 Entry $2.36 to $2.25 Now $1.21 +48.73% ▲ +4.66% +4.72% vs SPY
- Mar 25, 202633w ago 8-K Bearish 6/10 Entry $2.14 to $2.06 Now $1.21 +43.46% ▲ +3.74% +2.06% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers